Highlights
– The German nationwide SCD‑PROTECT registry enrolled 19,598 patients with newly diagnosed reduced LVEF and showed a substantial early incidence of sustained VT/VF requiring WCD therapy in both non‑ischaemic (6.10 first treatments/100 patient‑years) and ischaemic (8.64/100 patient‑years) cohorts.
– Overall appropriate WCD therapy incidence (all events) was 8.53 and 14.98 events/100 patient‑years for NICM and MI/CAD groups, respectively; inappropriate shocks were rare (0.5%) and total mortality during WCD use was low (0.8%).
